Drug Profile


Alternative Names: GC-1008

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Genzyme Corporation
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fibrosis; Malignant melanoma; Pulmonary fibrosis; Renal cancer
  • Discontinued Focal segmental glomerulosclerosis

Most Recent Events

  • 16 Oct 2015 National Cancer Institute plans a phase I/II trial for Non-small cell lung cancer in USA (NCT02581787)
  • 04 Sep 2015 No recent reports of development identified - Phase-I for Pulmonary fibrosis in USA (IV)
  • 04 Sep 2015 No recent reports of development identified - Phase-II for Fibrosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top